Where we Invest
We seek companies developing technologies that address clinical needs across reconstructive and aesthetic surgery.
Wound Care & Biomaterials
Regenerative Medicine & Tissue Engineering
Surgical Robotics & Automation
Nerve Repair & Microsurgery
Aesthetic Devices & Digital Therapeutics
AI, Imaging & Surgical Planning
Our Process
-
01
Apply
Submit your company for initial consideration.
-
02
Screen
Our team conducts an initial review for strategic fit, traction and regulatory readiness.
-
03
Pitch
Selected companies are invited to present to the ASPS Ventures.
-
04
Due Diligence
Selected companies undergo due diligence, evaluating clinical, commercial, financial and strategic aspects of the company.
-
05
Investment
Approved companies receive investment and strategic support from ASPS Ventures.
Our Vision
To ensure that the future of plastic surgery is shaped by those who practice it.
By investing in clinically meaningful technologies, ASPS Ventures safeguards the specialty's leadership role, improves care for millions of patients and creates sustainable long-term value for investors and the Society.
What Makes ASPS Ventures a Credible GP?
- Institutional stability
- Institutional governance
- Balance-sheet strength
- Surgeon-led diligence
- Long-term alignment
- Mission-backed platform
What Makes Us Different?
Our greatest asset – and the core value to co-investors – is the active participation of ASPS Key Opinion Leaders (KOLs).
- They screen and select companies based on real clinical need.
- They participate directly in due diligence, product evaluation and early validation.
- They provide founders with expert guidance on regulatory pathways, clinical trials, surgical workflow integration and adoption dynamics.
This deep clinical involvement is not available in traditional VC funds, giving ASPS-vetted portfolio companies a materially higher probability of achieving product-market fit, surgeon adoption and strategic exit.
Through our partnership with MedTech Innovator (MTI), a leading accelerator for emerging medical technology companies, ASPS Ventures gains early access to promising companies across the medtech landscape.
Each year, ASPS Ventures works with a select group of MTI companies, providing surgeon mentorship, clinical feedback and strategic guidance as they refine their technologies and prepare for growth. This relationship gives the fund visibility into high-potential companies earlier in their development—before many reach the broader venture market.
ASPS Ventures is backed by the institutional strength and governance of the American Society of Plastic Surgeons, providing a level of stability and long-term alignment that is uncommon in venture investing.
Investment decisions are informed by experienced plastic surgery leaders and surgeon-led diligence, combining clinical judgment with disciplined oversight. The result is a mission-backed platform built to create lasting value for portfolio companies, investors and the specialty.
- Institutional stability
- Institutional governance
- Balance-sheet strength
- Surgeon-led diligence
- Long-term alignment
- Mission-backed platform
ASPS gives portfolio companies a direct connection to the plastic surgery community, including practicing surgeons, clinical experts, industry partners and leading channels within the specialty.
That access can help companies gather feedback, validate market needs, build relationships and gain visibility as they prepare to enter and grow within the market.
Plastic and reconstructive surgery sits at the center of several high-growth healthcare markets.
- Regenerative medicine
- Robotics and surgical automation
- AI-driven diagnostics and imaging
- Wound healing and tissue regeneration
- Nerve repair and limb salvage
- Aesthetic devices and digital therapeutics
These are expansion markets – large, growing and strategically important, yet fragmented and often overlooked by large generalist VCs.
